Cargando…
Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women
SUMMARY: Biosimilar teriparatide (INTG-8) was tested in a healthy population of males and postmenopausal females to assess pharmacokinetic bioequivalence to originator teriparatide comparator products. Primary pharmacokinetic comparison confirmed bioequivalence. Pharmacodynamics, safety, and tolerab...
Autores principales: | Fenwick, Steven, Vekariya, Vishal, Patel, Ronak, Hajela, Pallavi, Modi, Ketul, Kale, Prashant, Nath, Akshaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813072/ https://www.ncbi.nlm.nih.gov/pubmed/36287230 http://dx.doi.org/10.1007/s00198-022-06573-x |
Ejemplares similares
-
Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010) -
Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010) -
Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012) -
Teriparatide treatment for postmenopausal women with sacral insufficiency fracture
por: Kim, Young-Hoon
Publicado: (2023) -
Reply on “teriparatide treatment for postmenopausal women with sacral insufficiency fracture”
por: Yang, Yao-Chun, et al.
Publicado: (2023)